

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1 - 37. (Canceled)

38. (Currently Amended) An *in vitro* method of functionally determining at physiological conditions deficiencies in the lectin pathway of the complement system, employing in a sample of mammalian blood, serum, or plasma, or another body fluid obtained from a mammal, the method comprising the steps of

- (a) adding ~~an~~ C1 complex inhibitor ~~to the sample to inhibit a classical pathway of complement, the C1 complex inhibitor comprising:~~selected from the group consisting of

an inhibitory C1q-binding protein[[s]] selected from the group consisting of C1 inhibitor, CRT, C1q_r, E.coli C1g binding protein, gC1q_r, ghB3, decorin, chondroitin sulphate proteoglycan, and surfactant protein A,

peptidesa peptide inhibitor of C1q, C1_r or C1s selected from the group consisting of TDGDKAFVDFLSDEIKEE (SEQ ID NO. 1), KDIRCKDD (SEQ ID NO. 2), AEAKAKA (SEQ ID NO. 3), VQVHNAKTKPR (SEQ ID NO. 4), WY, CEGPFGPRHDLTFCW (SEQ ID NO. 5), and-LEQGENVFLQATLL (SEQ ID NO. 6), CRWDGSWGEVRC (SEQ ID NO. 7), CMWVRMWGDVNC (SEQ ID NO. 8), CFWAGKFGLGTC (SEQ ID NO. 9), CKDRWVVEERCC (SEQ ID NO. 10), and CWNRFKKMDRC (SEQ ID NO. 11), or

an immunoglobulin[[s]] that binds against-C1q, C1_r or C1s;

- (b) diluting the sample with a buffered aqueous media having physiological pH and physiological ion strength to inhibit the activation of the an alternative pathway of complement;
- (c) adding a MBL-(mannan-binding lectin) (MBL) or ficolin binding carbohydrate to activate activating the lectin pathway of complement in the sample;

- (d) adding ~~ana~~ first antibody ~~against the~~ to the sample that specifically binds autologous-C5b-9 complex to detect formation of C5b-9 complex in the sample, and
- (e) ~~determining the activation of the lectin pathway in the sample at the physiological condition~~conditions by measuring the autologous amount of C5b-9 complex detected in the sample.

39. (Canceled)

40. (Canceled)

41. (Currently Amended) The method according to claim 38, wherein ~~the said~~ inhibitor in step (a) is an immunoglobulin selected from the group consisting of polyclonal and monoclonal antibodies.

42. (Currently Amended) The method according to claim 38, wherein ~~the said~~ carbohydrate in step (e) is selected from the group consisting of mannose, fucose, or mannan such as glucomannan and galactomannan, synthetic carbohydrate and microbial polysaccharide.

43. (Currently Amended) The method according to claim 38, wherein ~~the said~~ first antibody in step (d) is a polyclonal or a monoclonal antibody.

44. (Currently Amended) The method according to claim ~~[[43]]~~38, wherein the step in (d) comprises adding a second antibody that binds the said first antibody, wherein said second antibody is a labeled antibody.

45. (Currently Amended) The method according to claim 43, wherein ~~the said~~ first antibody is a labeled antibody.

46. (Withdrawn - Currently Amended) A kit for functionally determining deficiencies in a lectin pathway of complement in a body fluid from a mammal, the kit comprising:

(a) an inert carrier and a mannan-binding lectin (MBL) or ficolin binding carbohydrate for activating the lectin pathway of complement;

(b) a diluent comprising a C1 complex inhibitor for inhibiting a classical pathway of complement, the C1 complex inhibitor comprising: ~~selected from the group consisting of~~

an inhibitory C1q-binding protein[[s]] selected from the group consisting of C1 inhibitor, CRT, C1Or, E.coli C1g binding protein, gC1qR, ghB3, decorin, chondroitin sulphate proteoglycan, and surfactant protein A,

_____ peptides a peptide inhibitor of C1q, C1r or C1s selected from the group consisting of TDGDKAFVDFLSDEIKEE (SEQ ID NO. 1), KDIRCKDD (SEQ ID NO. 2), AEAKAKA (SEQ ID NO. 3), VQVHNAKTKPR (SEQ ID NO. 4), WY, CEGPFGPRHDLTFCW (SEQ ID NO. 5), and LEQGENVFLQATLL (SEQ ID NO. 6), CRWDGSWGEVRC (SEQ ID NO. 7), CMWVRMWGDVNC (SEQ ID NO. 8), CFWAGKFGLGTC (SEQ ID NO. 9), CKDRWVVEERCC (SEQ ID NO. 10), and CWNRFKKMDRC (SEQ ID NO. 11), or

_____ an immunoglobulin[[s]] that binds against C1q, C1r or C1s; and

(c) a first antibody that specifically binds a ~~against the autologous C5b-9 complex, for functionally determining in a body fluid from a mammal deficiencies in the lectin pathway of the complement system.~~

47. (Withdrawn – Currently Amended) The kit according to claim 46, wherein the carbohydrate in (a) is selected from the group consisting of mannose, fucose, or mannan-such-as-glucomannan and galactormannan, synthetic carbohydrate and microbial polysaccharide.

48. (Canceled)

49. (Canceled)

50. (Withdrawn – Currently Amended) The kit according to claim 46, wherein the inhibitor in (b) is an immunoglobulin selected from the group consisting of polyclonal and monoclonal antibodies.

51. (Withdrawn) The kit according to claim 46, wherein the first antibody in (c) is a polyclonal or monoclonal antibody.

52. (Withdrawn) The kit according to claim 47, wherein the carbohydrate in (a) is coated on the inert carrier.

53. (Withdrawn) The kit according to claim 51, wherein the first antibody in (c) is a labeled antibody.

54. (Withdrawn – Currently Amended) The kit according to claim ~~[[51]]~~46, wherein the kit further comprises a labeled second antibody (d) ~~against that binds~~ the first antibody in (c).

55. (Withdrawn) The kit according to claim 53, wherein the kit further comprises an enzyme substrate (e).

56. (Withdrawn) The kit according to claims 46, wherein the kit further comprises a washing solution (f).

57. (Withdrawn) The kit according to claim 46, wherein the kit further comprises a normal body liquid from a mammal (g).

58. (Withdrawn) The kit according to claim 57, wherein the normal body liquid (g) is a human serum.

59. (Withdrawn) The kit according to claim 46, wherein the kit further comprises an inactivated normal body liquid from a mammal (h).

60. (Withdrawn) The kit according to claim 59, wherein the inactivated normal body liquid (h) is heat inactivated human serum.

61. (New) The method according to claim 42, wherein said mannan is glucomannan or galactomannan.

62. (New) The kit according to claim 47, wherein said mannan is glucomannan or galactomannan.